{"id":"influenza-virus-split-vaccine","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Injection site pain"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"The disruption of the virus particles exposes the internal proteins and hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins, which are key targets for the immune system. This leads to the production of antibodies that can neutralize the virus and prevent infection.","oneSentence":"Influenza virus split vaccines contain inactivated influenza viruses that have been disrupted to release viral antigens, which stimulate an immune response against the influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:11:46.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza caused by virus strains included in the vaccine"}]},"trialDetails":[{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT07349017","phase":"PHASE1","title":"A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-02-07","conditions":"Influenza","enrollment":160},{"nctId":"NCT07327398","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2026-01-07","conditions":"Influenza","enrollment":1200},{"nctId":"NCT07302256","phase":"PHASE1","title":"A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-12-16","conditions":"Influenza","enrollment":120},{"nctId":"NCT05645900","phase":"PHASE3","title":"A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-02-06","conditions":"Influenza","enrollment":2772},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT00800605","phase":"PHASE3","title":"Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-12","conditions":"Influenza","enrollment":7250},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT06342349","phase":"PHASE1","title":"A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-03-30","conditions":"Influenza","enrollment":300},{"nctId":"NCT06800950","phase":"PHASE3","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-02-08","conditions":"Influenza, Human, Influenza, Human Prevention, Influenza a","enrollment":4400},{"nctId":"NCT06622590","phase":"PHASE1","title":"Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-10-13","conditions":"Influenza, Human, Influenza a, Influenza Type B","enrollment":180},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT03160118","phase":"PHASE4","title":"Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-03-27","conditions":"Prevention of Influenza","enrollment":20},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT06334510","phase":"","title":"Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-11-17","conditions":"GCP","enrollment":4900},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT00566345","phase":"PHASE3","title":"Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-11","conditions":"Influenza","enrollment":3670},{"nctId":"NCT01551823","phase":"PHASE3","title":"The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Influenza","enrollment":1200},{"nctId":"NCT01551810","phase":"PHASE3","title":"The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Influenza","enrollment":1200},{"nctId":"NCT05138705","phase":"PHASE4","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2021-12-14","conditions":"Influenza, Human","enrollment":380},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT04176133","phase":"PHASE2","title":"Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination","status":"COMPLETED","sponsor":"Robert J. Pignolo","startDate":"2019-10-30","conditions":"Healthy","enrollment":61},{"nctId":"NCT05107375","phase":"PHASE3","title":"Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-09-03","conditions":"Coronavirus Disease 2019","enrollment":299},{"nctId":"NCT03930017","phase":"","title":"Pregnancy, Arsenic and Immune Response","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-10-14","conditions":"Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired","enrollment":784},{"nctId":"NCT05212623","phase":"PHASE1","title":"A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-10-26","conditions":"Influenza","enrollment":120},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT05389137","phase":"PHASE4","title":"To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years","status":"UNKNOWN","sponsor":"Wuhan Institute of Biological Products Co., Ltd","startDate":"2022-03-02","conditions":"Influenza","enrollment":360},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT03589807","phase":"PHASE2","title":"2013/2017 H7N9 Prime-Boost Interval","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-21","conditions":"Avian Influenza, Influenza Immunisation","enrollment":180},{"nctId":"NCT03738241","phase":"PHASE2","title":"2017 A/H7N9 IIV Revaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-18","conditions":"Avian Influenza, Influenza Immunisation","enrollment":304},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT01157702","phase":"PHASE3","title":"Yearly Strain Variation Study, 2010/2011","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2010-07","conditions":"Influenza, Seasonal Influenza","enrollment":110},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT00449670","phase":"PHASE3","title":"Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-24","conditions":"Influenza, Influenza Vaccines","enrollment":1206},{"nctId":"NCT02894840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":"Influenza","enrollment":340},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT00385255","phase":"PHASE3","title":"Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-23","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":1726},{"nctId":"NCT00138398","phase":"NA","title":"T-cell Response-Flu Risk in Older Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10-25","conditions":"Influenza","enrollment":850},{"nctId":"NCT00502593","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":"Influenza","enrollment":138},{"nctId":"NCT01215669","phase":"PHASE4","title":"Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":240},{"nctId":"NCT01811823","phase":"PHASE4","title":"Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-03-31","conditions":"Influenza, HIV, Tuberculosis","enrollment":301},{"nctId":"NCT00319098","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Influenza","enrollment":5075},{"nctId":"NCT03572491","phase":"PHASE3","title":"Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2017-09-18","conditions":"Human Influenza","enrollment":2000},{"nctId":"NCT03016143","phase":"PHASE2","title":"Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-10","conditions":"Influenza","enrollment":300},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT00735475","phase":"PHASE4","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":1268},{"nctId":"NCT02100436","phase":"PHASE2","title":"Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-06-11","conditions":"Influenza","enrollment":270},{"nctId":"NCT02213354","phase":"PHASE2","title":"H7N9 Mix and Match With MF59 in Healthy Elderly Persons","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-10","conditions":"Avian Influenza","enrollment":479},{"nctId":"NCT03196661","phase":"PHASE1","title":"Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2015-11-06","conditions":"Influenza A","enrollment":588},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT01518478","phase":"EARLY_PHASE1","title":"Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-11","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT02255279","phase":"PHASE3","title":"Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-10","conditions":"Influenza","enrollment":287},{"nctId":"NCT03028116","phase":"PHASE1","title":"Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-05","conditions":"Influenza, Human","enrollment":44},{"nctId":"NCT01666782","phase":"PHASE2","title":"Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy","status":"COMPLETED","sponsor":"Saad Jamshed MD","startDate":"2012-08","conditions":"Cancer, Influenza Viral Infections","enrollment":105},{"nctId":"NCT00551031","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Myxovirus Infection","enrollment":2098},{"nctId":"NCT00391053","phase":"PHASE3","title":"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3851},{"nctId":"NCT00524940","phase":"PHASE2","title":"Trial to Describe the Safety and Immunogenicity of Fluzone®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-08","conditions":"Influenza","enrollment":124},{"nctId":"NCT00772109","phase":"PHASE3","title":"Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":4292},{"nctId":"NCT02263027","phase":"PHASE4","title":"Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines?","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-10","conditions":"Influenza","enrollment":11},{"nctId":"NCT00424086","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-01","conditions":"Influenza","enrollment":1000},{"nctId":"NCT00943657","phase":"PHASE3","title":"Yearly Strain Variation Study, 2009/2010","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-06","conditions":"Influenza, Seasonal Influenza","enrollment":110},{"nctId":"NCT01138397","phase":"PHASE3","title":"Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-06","conditions":"Influenza","enrollment":129},{"nctId":"NCT01121822","phase":"PHASE3","title":"Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-05","conditions":"Influenza","enrollment":129},{"nctId":"NCT01032980","phase":"","title":"Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12","conditions":"Influenza, Swine-Origin A/H1N1 Influenza Virus","enrollment":3934},{"nctId":"NCT00776438","phase":"PHASE2","title":"Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Influenza, Orthomyxovirus Infections, Myxovirus Infection","enrollment":160},{"nctId":"NCT00170547","phase":"PHASE2","title":"Comparison of Delivery Routes of Flu Vaccine in Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Influenza","enrollment":1597},{"nctId":"NCT00784784","phase":"PHASE3","title":"Zanamivir Versus Trivalent Split Virus Influenza Vaccine","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2008-11","conditions":"Influenza","enrollment":64},{"nctId":"NCT02136017","phase":"","title":"Post-License Safety Evaluation of Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Sichuan Center for Disease Control and Prevention","startDate":"2013-01","conditions":"Influenza, Adverse Drug Event","enrollment":400000},{"nctId":"NCT00718146","phase":"PHASE2","title":"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":130},{"nctId":"NCT00343681","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":120},{"nctId":"NCT00491257","phase":"PHASE2","title":"A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":130},{"nctId":"NCT00946179","phase":"PHASE2","title":"Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-05","conditions":"Influenza","enrollment":130},{"nctId":"NCT00491985","phase":"PHASE2","title":"Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-06","conditions":"Influenza, Orthomyxoviridae Infections, Influenza A Virus Infection","enrollment":240},{"nctId":"NCT00383526","phase":"PHASE3","title":"Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3707},{"nctId":"NCT00884182","phase":"PHASE2","title":"Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-04","conditions":"Influenza, Orthomyxoviridae Infections, Orthomyxovirus Infections","enrollment":350},{"nctId":"NCT01053143","phase":"PHASE3","title":"Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-01","conditions":"Influenza, Pandemic Influenza, Influenza A Virus, H1N1 Subtype","enrollment":100},{"nctId":"NCT00956046","phase":"PHASE2","title":"A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-09","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":401},{"nctId":"NCT00296829","phase":"PHASE2","title":"Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-01","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":1080},{"nctId":"NCT00415129","phase":"PHASE2","title":"Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":600},{"nctId":"NCT00945438","phase":"PHASE2","title":"Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-05","conditions":"Influenza","enrollment":131},{"nctId":"NCT00545701","phase":"PHASE2","title":"Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-10","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":100},{"nctId":"NCT00383539","phase":"PHASE3","title":"Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":2256},{"nctId":"NCT00606359","phase":"PHASE2","title":"Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-11","conditions":"Influenza, Orthomyxoviridae Infections","enrollment":62},{"nctId":"NCT00457509","phase":"PHASE1","title":"Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-01","conditions":"Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections","enrollment":251},{"nctId":"NCT00258934","phase":"PHASE2","title":"Immunogenicity Study of the Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-09","conditions":"Orthomyxoviridae Infections, Influenza","enrollment":978},{"nctId":"NCT00703651","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-09","conditions":"Influenza, Orthomyxoviridae Infection, Myxovirus Infection","enrollment":1150},{"nctId":"NCT00775450","phase":"PHASE2","title":"Influenza Vaccine Revaccination in Ambulatory Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-10","conditions":"Influenza, Orthomyxovirus Infection, Myxovirus Infection","enrollment":807}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Influenza virus split vaccine","genericName":"Influenza virus split vaccine","companyName":"Jiangsu Province Centers for Disease Control and Prevention","companyId":"jiangsu-province-centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"Influenza virus split vaccines contain inactivated influenza viruses that have been disrupted to release viral antigens, which stimulate an immune response against the influenza virus. Used for Prevention of influenza caused by virus strains included in the vaccine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}